Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Bipolar disorder in adults: Managing poor adherence to maintenance pharmacotherapy

Eduard Vieta, MD, PhD
Francesc Colom, PhD, PsyD, MSc
Section Editor
Paul Keck, MD
Deputy Editor
David Solomon, MD


Adherence to pharmacotherapy is often poor in chronic medical illnesses, including bipolar disorder [1-3]. Poor adherence is usually addressed during maintenance-phase treatment when patients are euthymic and stable.

This topic reviews management of poor adherence to medications in bipolar disorder. Selecting a treatment regimen for maintenance treatment of bipolar disorder and the adjunctive psychotherapies that are used for maintenance treatment are discussed separately. (See "Bipolar disorder in adults: Choosing maintenance treatment" and "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies".)


Bipolar disorder — Bipolar disorder is a mood disorder that is characterized by episodes of mania (table 1), hypomania (table 2), and major depression (table 3) [4]. The subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic episodes, and nearly always experience hypomanic and major depressive episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See "Bipolar disorder in adults: Clinical features" and "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'.)

Medication adherence — Adherence to pharmacotherapy encompasses taking medication as prescribed with regard to dose, frequency, and timing [5]. Adherence can be quantified on a continuum as a percentage of doses taken as prescribed during a specific interval, or expressed categorically as good, partial, and poor adherence [6]. It is not known what level of adherence is required for good outcomes such as avoiding relapse. Common but arbitrary cutoffs for good adherence are taking at least 70 or 80 percent of prescribed doses. Adherence within patients can change over time and vary between different drugs [7].


Prevalence — Many studies have found that poor adherence with pharmacotherapy occurs in roughly 50 percent of bipolar patients [7-19]. As an example:


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 7, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381:1672.
  2. Anderson IM, Haddad PM, Scott J. Bipolar disorder. BMJ 2012; 345:e8508.
  3. Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. JAMA 2013; 310:2611.
  4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
  5. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11:44.
  6. Busby KK, Sajatovic M. REVIEW: Patient, treatment, and systems-level factors in bipolar disorder nonadherence: A summary of the literature. CNS Neurosci Ther 2010; 16:308.
  7. Arvilommi P, Suominen K, Mantere O, et al. Predictors of adherence to psychopharmacological and psychosocial treatment in bipolar I or II disorders - an 18-month prospective study. J Affect Disord 2014; 155:110.
  8. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006; 8:232.
  9. Lang K, Korn J, Muser E, et al. Predictors of medication nonadherence and hospitalization in Medicaid patients with bipolar I disorder given long-acting or oral antipsychotics. J Med Econ 2011; 14:217.
  10. Fleck DE, Keck PE Jr, Corey KB, Strakowski SM. Factors associated with medication adherence in African American and white patients with bipolar disorder. J Clin Psychiatry 2005; 66:646.
  11. Hou R, Cleak V, Peveler R. Do treatment and illness beliefs influence adherence to medication in patients with bipolar affective disorder? A preliminary cross-sectional study. Eur Psychiatry 2010; 25:216.
  12. Colom F, Vieta E, Martínez-Arán A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000; 61:549.
  13. Strakowski SM, Keck PE Jr, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998; 55:49.
  14. Keck PE Jr, McElroy SL, Strakowski SM, et al. Compliance with maintenance treatment in bipolar disorder. Psychopharmacol Bull 1997; 33:87.
  15. Morselli PL, Elgie R, GAMIAN-Europe. GAMIAN-Europe/BEAM survey I--global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord 2003; 5:265.
  16. Zeber JE, Copeland LA, Good CB, et al. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. J Affect Disord 2008; 107:53.
  17. Martinez-Aran A, Scott J, Colom F, et al. Treatment nonadherence and neurocognitive impairment in bipolar disorder. J Clin Psychiatry 2009; 70:1017.
  18. Bates JA, Whitehead R, Bolge SC, Kim E. Correlates of medication adherence among patients with bipolar disorder: results of the bipolar evaluation of satisfaction and tolerability (BEST) study: a nationwide cross-sectional survey. Prim Care Companion J Clin Psychiatry 2010; 12.
  19. Craig TJ, Grossman S, Mojtabai R, et al. Medication use patterns and 2-year outcome in first-admission bipolar disorder with psychotic features. Bipolar Disord 2004; 6:406.
  20. Sajatovic M, Valenstein M, Blow F, et al. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58:855.
  21. Moon E, Chang JS, Kim MY, et al. Dropout rate and associated factors in patients with bipolar disorders. J Affect Disord 2012; 141:47.
  22. Bagalman E, Yu-Isenberg KS, Durden E, et al. Indirect costs associated with nonadherence to treatment for bipolar disorder. J Occup Environ Med 2010; 52:478.
  23. Sylvia LG, Reilly-Harrington NA, Leon AC, et al. Medication adherence in a comparative effectiveness trial for bipolar disorder. Acta Psychiatr Scand 2014; 129:359.
  24. Velligan DI, Weiden PJ, Sajatovic M, et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract 2010; 16:34.
  25. Velligan DI, Weiden PJ, Sajatovic M, et al. Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010; 16:306.
  26. Berk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol 2010; 25:1.
  27. Sajatovic M, Ignacio RV, West JA, et al. Predictors of nonadherence among individuals with bipolar disorder receiving treatment in a community mental health clinic. Compr Psychiatry 2009; 50:100.
  28. González-Pinto A, Reed C, Novick D, et al. Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 2010; 43:263.
  29. Sajatovic M, Bauer MS, Kilbourne AM, et al. Self-reported medication treatment adherence among veterans with bipolar disorder. Psychiatr Serv 2006; 57:56.
  30. Baldessarini RJ, Perry R, Pike J. Factors associated with treatment nonadherence among US bipolar disorder patients. Hum Psychopharmacol 2008; 23:95.
  31. Hong J, Reed C, Novick D, et al. Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study. Psychiatry Res 2011; 190:110.
  32. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord 2006; 8:618.
  33. Sajatovic M, Levin J, Fuentes-Casiano E, et al. Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication. Compr Psychiatry 2011; 52:280.
  34. Colom F, Berk L. Psychoeducation as a core element of psychological approaches for bipolar disorders. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M. (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.412.
  35. Jónsdóttir H, Opjordsmoen S, Birkenaes AB, et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 2013; 127:23.
  36. Devulapalli KK, Ignacio RV, Weiden P, et al. Why do persons with bipolar disorder stop their medication? Psychopharmacol Bull 2010; 43:5.
  37. Pope M, Scott J. Do clinicians understand why individuals stop taking lithium? J Affect Disord 2003; 74:287.
  38. Gianfrancesco FD, Sajatovic M, Tafesse E, Wang RH. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder. Ann Clin Psychiatry 2009; 21:3.
  39. Keck PE Jr, McElroy SL, Strakowski SM, et al. Factors associated with pharmacologic noncompliance in patients with mania. J Clin Psychiatry 1996; 57:292.
  40. Murru A, Pacchiarotti I, Amann BL, et al. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 2013; 151:1003.
  41. Belzeaux R, Boyer L, Mazzola-Pomietto P, et al. Adherence to medication is associated with non-planning impulsivity in euthymic bipolar disorder patients. J Affect Disord 2015; 184:60.
  42. Connelly CE, Davenport YB, Nurnberger JI Jr. Adherence to treatment regimen in a lithium carbonate clinic. Arch Gen Psychiatry 1982; 39:585.
  43. Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective study. Ann Gen Psychiatry 2009; 8:7.
  44. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009; 66:358.
  45. Lew KH, Chang EY, Rajagopalan K, Knoth RL. The effect of medication adherence on health care utilization in bipolar disorder. Manag Care Interface 2006; 19:41.
  46. Gutiérrez-Rojas L, Jurado D, Martínez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010; 127:77.
  47. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333:15.
  48. Scott J, Tacchi MJ. Treatment adherence in bipolar disorder. In: Bipolar Disorder: Clinical and Neurobiological Foundations, Yatham LN, Maj M. (Eds), Wiley-Blackwell, West Sussex, UK 2010. p.275.
  49. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry 2009; 70 Suppl 4:1.
  50. Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord 2005; 7 Suppl 5:24.
  51. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.
  52. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6:504.
  53. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, third edition. Am J Psychiatry 2010; 167 (supplement):1.
  54. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. http://www.psychiatry.org/practice/clinical-practice-guidelines (Accessed on July 09, 2014).
  55. Strauss JL, Johnson SL. Role of treatment alliance in the clinical management of bipolar disorder: stronger alliances prospectively predict fewer manic symptoms. Psychiatry Res 2006; 145:215.
  56. Sylvia LG, Hay A, Ostacher MJ, et al. Association between therapeutic alliance, care satisfaction, and pharmacological adherence in bipolar disorder. J Clin Psychopharmacol 2013; 33:343.
  57. Horvath AO, Greenberg LS. Working Alliance Inventory. In: Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D. (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.187.
  58. Stephenson JJ, Tunceli O, Gu T, et al. Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims. Int J Clin Pract 2012; 66:565.
  59. Medic G, Higashi K, Littlewood KJ, et al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatr Dis Treat 2013; 9:119.
  60. Makela EH, Griffith RK. Enhancing treatment of bipolar disorder using the patient's belief system. Ann Pharmacother 2003; 37:543.
  61. Bingel U, Placebo Competence Team. Avoiding nocebo effects to optimize treatment outcome. JAMA 2014; 312:693.
  62. Kleindienst N, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J Clin Psychiatry 2004; 65:966.
  63. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord 2013; 149:247.
  64. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60:402.
  65. Colom F, Vieta E, Sánchez-Moreno J, et al. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 2005; 7 Suppl 5:32.
  66. Eker F, Harkın S. Effectiveness of six-week psychoeducation program on adherence of patients with bipolar affective disorder. J Affect Disord 2012; 138:409.
  67. Harvey NS, Peet M. Lithium maintenance: 2. Effects of personality and attitude on health information acquisition and compliance. Br J Psychiatry 1991; 158:200.
  68. D'Souza R, Piskulic D, Sundram S. A brief dyadic group based psychoeducation program improves relapse rates in recently remitted bipolar disorder: a pilot randomised controlled trial. J Affect Disord 2010; 120:272.
  69. Parikh SV, Zaretsky A, Beaulieu S, et al. A randomized controlled trial of psychoeducation or cognitive-behavioral therapy in bipolar disorder: a Canadian Network for Mood and Anxiety treatments (CANMAT) study [CME]. J Clin Psychiatry 2012; 73:803.
  70. Colom F. Keeping therapies simple: psychoeducation in the prevention of relapse in affective disorders. Br J Psychiatry 2011; 198:338.
  71. Szentagotai A, David D. The efficacy of cognitive-behavioral therapy in bipolar disorder: a quantitative meta-analysis. J Clin Psychiatry 2010; 71:66.
  72. Miklowitz DJ, George EL, Richards JA, et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60:904.
  73. Clarkin JF, Carpenter D, Hull J, et al. Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998; 49:531.
  74. McKenzie K, Chang YP. The effect of nurse-led motivational interviewing on medication adherence in patients with bipolar disorder. Perspect Psychiatr Care 2015; 51:36.
  75. Sajatovic M, Levin J, Tatsuoka C, et al. Customized adherence enhancement for individuals with bipolar disorder receiving antipsychotic therapy. Psychiatr Serv 2012; 63:176.
  76. Sajatovic M, Levin J, Tatsuoka C, et al. Six-month outcomes of customized adherence enhancement (CAE) therapy in bipolar disorder. Bipolar Disord 2012; 14:291.